Clinical Trials Logo

Clinical Trial Summary

This is a multi-center, open-label non-randomized dose-escalation trial of vorinostat given in combination with vinorelbine. Cohorts will be treated with a fixed dose of vinorelbine (25mg/m²/week continuously, representing the schedule that has been approved). Patients eligible will be enrolled into a standard 3+3 design with a starting dose of vorinostat at 200 mg po qd 7/21 (weekly schedule). Then, further dose levels will be explored. Toxicity of the schedule will be assessed during the first cycle. Patients may receive up to 6 cycles of study medication. Blood samples will be collected at specified time points to assess pharmacokinetic endpoints.


Clinical Trial Description

n/a


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00801151
Study type Interventional
Source Institut Claudius Regaud
Contact
Status Terminated
Phase Phase 1
Start date January 2009
Completion date November 2009

See also
  Status Clinical Trial Phase
Completed NCT01721148 - A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours Phase 1
Completed NCT00551096 - Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors Phase 1
Completed NCT01023737 - Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Phase 1
Completed NCT01435096 - BN80927 in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT01951846 - To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours Phase 1
Completed NCT01325558 - A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01554371 - Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT01286896 - Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT01309490 - Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Phase 1/Phase 2
Completed NCT00635791 - Phase I Study of Vorinostat and Sorafenib in Advanced Cancer Phase 1
Completed NCT01376505 - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Phase 1
Completed NCT00388427 - Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies Phase 1
Completed NCT01611857 - Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach Phase 1/Phase 2
Completed NCT02843204 - Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors Phase 1/Phase 2
Completed NCT02853903 - Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors Phase 2
Completed NCT01618136 - An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02786628 - Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT01184807 - Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors Phase 1
Completed NCT00969410 - A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases Phase 1
Completed NCT02857920 - Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors Phase 1/Phase 2